Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: ESAIY )

10.45 +0.02 (+0.16%)
Streaming Delayed Price Updated: 11:36 AM EDT, May 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 49,362
Open 10.40
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 10.43
Today's Range 10.29 - 10.55
52wk Range 9.310 - 18.87
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biogen Stock Continues Its 20% Sprint On A Twist In Alzheimer's Treatment
The company is hoping to launch an under-the-skin version of its infusion, Leqembi. 
Via Investor's Business Daily
Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline?
Biogen shares have lost nearly 40% of their value since last June. Could two key sales beats help revive shares? 
Via Investor's Business Daily
Topics Earnings
Exposures Financial

Performance

YTD
-15.42%
-15.42%
1 Month
+6.42%
+6.42%
3 Month
+1.65%
+1.65%
6 Month
-18.68%
-18.68%
1 Year
-38.34%
-38.34%

More News

Read More
3 Stocks Wall Street Is Ignoring (But You Shouldn’t): April Edition
Via InvestorPlace
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
Via Investor's Business Daily
Exposures Product Safety
3 Millionaire-Maker Stocks to Buy While the Gettin’ Is Good
Via InvestorPlace
Current Analysis: Eisai Co Ltd (ESAIY)
Via Talk Markets
Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million
Via Talk Markets
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
Via InvestorPlace
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Via Investor's Business Daily
3 Aging Population Stocks to Profit from the Boomer Generation
Via InvestorPlace
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
Via Benzinga
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
Via Investor's Business Daily
3 Biotech Moonshots to Bet on the Future of Health
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
The 3 Best Biotech Stocks to Buy Now: September 2023
Via InvestorPlace
3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes
Via InvestorPlace
All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings
Via Investor's Business Daily
Stock Futures Dip As Traders Eye Friday Jobs Report: Analyst Says Q3 Returns Hinge More On This Catalyst Than Fed Move
Via Benzinga
Biogen's Make-Or-Break Moment Is Here In Alzheimer's Treatment
Via Investor's Business Daily
Biogen Stock Halted As It Faces Make-Or-Break Moment For Alzheimer's Treatment
Via Investor's Business Daily
Biogen Rises As 'Relatively Benign' FDA Documents Suggest An Alzheimer's Approval Is Near
Via Investor's Business Daily
Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump
Via Investor's Business Daily
Eli Lilly's Alzheimer's Drug Is Just Version 1.0. But It's Still On Track For Blockbuster Status, Analyst Says.
Via Investor's Business Daily
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC
Via Talk Markets
IBD 50 Leader And No. 1 Biotech Catalyst Puts Up 128% Earnings Growth
Via Investor's Business Daily
Alzheimer's Drugs Still Aren't Biogen's Saving Grace — But The Company Is Hopeful
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.